Latest Breaking News On - Fda oncologic drugs advisory committee - Page 1 : comparemela.com

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

United statesKennethc andersonHarvard medical schoolLebow institute for myeloma therapeuticsFda oncologic drugs advisory committeeJerome lipper multiple myeloma centerDana farber cancer instituteLebow instituteMyeloma therapeuticsKraft family professorDrugs advisory committeeNorth americaDana farber cancer instituteOnclive tvMultiple myeloma